Cargando…
Understanding brain dysfunction in sepsis
Sepsis often is characterized by an acute brain dysfunction, which is associated with increased morbidity and mortality. Its pathophysiology is highly complex, resulting from both inflammatory and noninflammatory processes, which may induce significant alterations in vulnerable areas of the brain. I...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673822/ https://www.ncbi.nlm.nih.gov/pubmed/23718252 http://dx.doi.org/10.1186/2110-5820-3-15 |
_version_ | 1782272280882053120 |
---|---|
author | Sonneville, Romain Verdonk, Franck Rauturier, Camille Klein, Isabelle F Wolff, Michel Annane, Djillali Chretien, Fabrice Sharshar, Tarek |
author_facet | Sonneville, Romain Verdonk, Franck Rauturier, Camille Klein, Isabelle F Wolff, Michel Annane, Djillali Chretien, Fabrice Sharshar, Tarek |
author_sort | Sonneville, Romain |
collection | PubMed |
description | Sepsis often is characterized by an acute brain dysfunction, which is associated with increased morbidity and mortality. Its pathophysiology is highly complex, resulting from both inflammatory and noninflammatory processes, which may induce significant alterations in vulnerable areas of the brain. Important mechanisms include excessive microglial activation, impaired cerebral perfusion, blood–brain-barrier dysfunction, and altered neurotransmission. Systemic insults, such as prolonged inflammation, severe hypoxemia, and persistent hyperglycemia also may contribute to aggravate sepsis-induced brain dysfunction or injury. The diagnosis of brain dysfunction in sepsis relies essentially on neurological examination and neurological tests, such as EEG and neuroimaging. A brain MRI should be considered in case of persistent brain dysfunction after control of sepsis and exclusion of major confounding factors. Recent MRI studies suggest that septic shock can be associated with acute cerebrovascular lesions and white matter abnormalities. Currently, the management of brain dysfunction mainly consists of control of sepsis and prevention of all aggravating factors, including metabolic disturbances, drug overdoses, anticholinergic medications, withdrawal syndromes, and Wernicke’s encephalopathy. Modulation of microglial activation, prevention of blood–brain-barrier alterations, and use of antioxidants represent relevant therapeutic targets that may impact significantly on neurologic outcomes. In the future, investigations in patients with sepsis should be undertaken to reduce the duration of brain dysfunction and to study the impact of this reduction on important health outcomes, including functional and cognitive status in survivors. |
format | Online Article Text |
id | pubmed-3673822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer |
record_format | MEDLINE/PubMed |
spelling | pubmed-36738222013-06-06 Understanding brain dysfunction in sepsis Sonneville, Romain Verdonk, Franck Rauturier, Camille Klein, Isabelle F Wolff, Michel Annane, Djillali Chretien, Fabrice Sharshar, Tarek Ann Intensive Care Review Sepsis often is characterized by an acute brain dysfunction, which is associated with increased morbidity and mortality. Its pathophysiology is highly complex, resulting from both inflammatory and noninflammatory processes, which may induce significant alterations in vulnerable areas of the brain. Important mechanisms include excessive microglial activation, impaired cerebral perfusion, blood–brain-barrier dysfunction, and altered neurotransmission. Systemic insults, such as prolonged inflammation, severe hypoxemia, and persistent hyperglycemia also may contribute to aggravate sepsis-induced brain dysfunction or injury. The diagnosis of brain dysfunction in sepsis relies essentially on neurological examination and neurological tests, such as EEG and neuroimaging. A brain MRI should be considered in case of persistent brain dysfunction after control of sepsis and exclusion of major confounding factors. Recent MRI studies suggest that septic shock can be associated with acute cerebrovascular lesions and white matter abnormalities. Currently, the management of brain dysfunction mainly consists of control of sepsis and prevention of all aggravating factors, including metabolic disturbances, drug overdoses, anticholinergic medications, withdrawal syndromes, and Wernicke’s encephalopathy. Modulation of microglial activation, prevention of blood–brain-barrier alterations, and use of antioxidants represent relevant therapeutic targets that may impact significantly on neurologic outcomes. In the future, investigations in patients with sepsis should be undertaken to reduce the duration of brain dysfunction and to study the impact of this reduction on important health outcomes, including functional and cognitive status in survivors. Springer 2013-05-29 /pmc/articles/PMC3673822/ /pubmed/23718252 http://dx.doi.org/10.1186/2110-5820-3-15 Text en Copyright ©2013 Sonneville et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Sonneville, Romain Verdonk, Franck Rauturier, Camille Klein, Isabelle F Wolff, Michel Annane, Djillali Chretien, Fabrice Sharshar, Tarek Understanding brain dysfunction in sepsis |
title | Understanding brain dysfunction in sepsis |
title_full | Understanding brain dysfunction in sepsis |
title_fullStr | Understanding brain dysfunction in sepsis |
title_full_unstemmed | Understanding brain dysfunction in sepsis |
title_short | Understanding brain dysfunction in sepsis |
title_sort | understanding brain dysfunction in sepsis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673822/ https://www.ncbi.nlm.nih.gov/pubmed/23718252 http://dx.doi.org/10.1186/2110-5820-3-15 |
work_keys_str_mv | AT sonnevilleromain understandingbraindysfunctioninsepsis AT verdonkfranck understandingbraindysfunctioninsepsis AT rauturiercamille understandingbraindysfunctioninsepsis AT kleinisabellef understandingbraindysfunctioninsepsis AT wolffmichel understandingbraindysfunctioninsepsis AT annanedjillali understandingbraindysfunctioninsepsis AT chretienfabrice understandingbraindysfunctioninsepsis AT sharshartarek understandingbraindysfunctioninsepsis |